


PRODUCT INFORMATION



GSK2837808A

Item No. 20626

CAS Registry No.: 1445879-21-9
Formal Name: 3-[[3-[(cyclopropylamino)sulfonyl]-7-(2,4-dimethoxy-5-pyrimidinyl)-4-quinolinyl]amino]-5-(3,5-difluorophenoxy)-benzoic acid
MF: C₃₁H₂₅F₂N₅O₇S
FW: 649.6
Purity: ≥98%
UV/Vis.: λ_{max}: 223, 266 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

GSK2837808A is supplied as a crystalline solid. A stock solution may be made by dissolving the GSK2837808A in the solvent of choice, which should be purged with an inert gas. GSK2837808A is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of GSK2837808A in these solvents is approximately 30 mg/ml. GSK2837808A is also slightly soluble in ethanol.

GSK2837808A is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, GSK2837808A should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. GSK2837808A has a solubility of approximately 0.33 mg/ml in a 1:2 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

GSK2837808A is a potent inhibitor of lactate dehydrogenase (LDH) A and B (IC₅₀s = 2.6 and 0.43 nM, for human recombinant LDHA and LDHB, respectively).¹ It inhibits lactate production in Snu398 hepatocellular carcinoma cells in which LDHB expression is undetectable (EC₅₀ = 400 nM). GSK2837808A (10 μM) reduces glucose consumption in Snu398 but not HepG2 hepatocellular carcinoma cells. A panel of 30 cancer cell lines, with varying levels of LDHA and LDHB expression, shows differential sensitivities to GSK2837808A with EC₅₀s ranging from 400 nM to 30 μM. The potency of GSK2837808A does not correlate with LDHA, LDHB, or total LDH expression levels.

Reference

1. Billiard, J., Dennison, J.B., Briand, J., *et al.* Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells. *Cancer Metab.* **1(1)**, 19 (2013).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/03/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM